197 related articles for article (PubMed ID: 23673926)
61. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein.
Zhang L; Wang LS; Xu Y; Xia L; Chen WL; Zheng Y; Chen GQ
Chin J Physiol; 2006 Aug; 49(4):182-91. PubMed ID: 17058450
[TBL] [Abstract][Full Text] [Related]
62. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
[TBL] [Abstract][Full Text] [Related]
63. [Influence of AML1 and AML1-ETO on transcriptional regulation of nucb2 gene].
Zou B; Jin W; Li J; Shi JT; Zhang J; Wang KK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1482-6. PubMed ID: 20030931
[TBL] [Abstract][Full Text] [Related]
64. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor.
Wildonger J; Mann RS
Development; 2005 May; 132(10):2263-72. PubMed ID: 15829516
[TBL] [Abstract][Full Text] [Related]
65. AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation.
Bäsecke J; Schwieger M; Griesinger F; Schiedlmeier B; Wulf G; Trümper L; Stocking C
Leuk Lymphoma; 2005 Feb; 46(2):265-72. PubMed ID: 15621811
[TBL] [Abstract][Full Text] [Related]
66. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.
Elagib KE; Goldfarb AN
Cancer Lett; 2007 Jun; 251(2):179-86. PubMed ID: 17125917
[TBL] [Abstract][Full Text] [Related]
67. The leukemia associated nuclear corepressor ETO homologue genes MTG16 and MTGR1 are regulated differently in hematopoietic cells.
Ajore R; Kumar P; Dhanda RS; Gullberg U; Olsson I
BMC Mol Biol; 2012 Mar; 13():11. PubMed ID: 22443175
[TBL] [Abstract][Full Text] [Related]
68. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.
Wang L; Zhao WL; Yan JS; Liu P; Sun HP; Zhou GB; Weng ZY; Wu WL; Weng XQ; Sun XJ; Chen Z; Sun HD; Chen SJ
Cell Death Differ; 2007 Feb; 14(2):306-17. PubMed ID: 16778832
[TBL] [Abstract][Full Text] [Related]
69. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
70. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
71. AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia.
Zhou L; Wang Q; Chen X; Fu L; Zhang X; Wang L; Deng A; Li D; Liu J; Lv N; Wang L; Li Y; Liu D; Yu L; Dou L
Exp Hematol; 2017 Feb; 46():62-69. PubMed ID: 27725192
[TBL] [Abstract][Full Text] [Related]
72. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
[TBL] [Abstract][Full Text] [Related]
73. [Inhibitory effect of Rnai on AML1 -ETO fusion gene expression in leukemia cells].
Wei J; Li S; Wang C; Qin YW; Ma XX; Xie KC; Yan SK; Gao YR; Cai Q
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):607-10. PubMed ID: 19175988
[TBL] [Abstract][Full Text] [Related]
74. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.
Rhoades KL; Hetherington CJ; Harakawa N; Yergeau DA; Zhou L; Liu LQ; Little MT; Tenen DG; Zhang DE
Blood; 2000 Sep; 96(6):2108-15. PubMed ID: 10979955
[TBL] [Abstract][Full Text] [Related]
75. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein.
Jakubowiak A; Pouponnot C; Berguido F; Frank R; Mao S; Massague J; Nimer SD
J Biol Chem; 2000 Dec; 275(51):40282-7. PubMed ID: 11032826
[TBL] [Abstract][Full Text] [Related]
76. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.
Shia WJ; Okumura AJ; Yan M; Sarkeshik A; Lo MC; Matsuura S; Komeno Y; Zhao X; Nimer SD; Yates JR; Zhang DE
Blood; 2012 May; 119(21):4953-62. PubMed ID: 22498736
[TBL] [Abstract][Full Text] [Related]
77. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain.
Plevin MJ; Zhang J; Guo C; Roeder RG; Ikura M
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10242-10247. PubMed ID: 16803958
[TBL] [Abstract][Full Text] [Related]
78. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
[TBL] [Abstract][Full Text] [Related]
79. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
[TBL] [Abstract][Full Text] [Related]
80. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression.
Gao FH; Wang Q; Wu YL; Li X; Zhao KW; Chen GQ
Biochem Biophys Res Commun; 2007 May; 356(2):505-11. PubMed ID: 17367753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
